SCHEDULE: abrdn Group Discloses 8.94% Stake in Quoin Pharmaceuticals
Beneficial Ownership Disclosure
Aberdeen Group plc and its subsidiary abrdn Inc. have disclosed a beneficial ownership of 8.94% in Quoin Pharmaceuticals, Ltd. through American Depositary Shares.
Summary
- Aberdeen Group plc and its subsidiary abrdn Inc. have filed a Schedule 13G, reporting beneficial ownership in Quoin Pharmaceuticals, Ltd.
- The filing indicates that abrdn Inc. beneficially owns 75,000 American Depositary Shares (ADS) of Quoin Pharmaceuticals, Ltd.
- Each ADS represents thirty-five (35) Ordinary Shares, no par value per share.
- This ownership stake represents 8.94% of the class of securities.
- Both Aberdeen Group plc and abrdn Inc. report shared voting power and shared dispositive power over all 75,000 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of beneficial ownership, which is generally neutral. However, the disclosure of a significant stake (8.94%) by a reputable institutional investor like abrdn can be perceived as a positive signal of confidence in the issuer, Quoin Pharmaceuticals, Ltd., by the market.
Positives
- The disclosure of a significant institutional investor like abrdn Inc. holding an 8.94% stake can signal confidence in Quoin Pharmaceuticals, Ltd. to other investors.
- The acquisition of shares in the ordinary course of business suggests a long-term investment strategy rather than an activist intent.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investment in Quoin Pharmaceuticals, a common occurrence in the pharmaceutical sector where specialized funds often take positions in companies with promising drug pipelines or market potential. The disclosure by abrdn, a major global investment company, suggests a strategic allocation within their managed portfolios.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holder may increase investor confidence and potentially influence trading activity.
- Management: Awareness of a large institutional holder may influence strategic decisions, though the filing states no intent to influence control.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event which required the filing of this statement (end of reporting period for beneficial ownership). |
| 01/20/2026 | Signature date of the Schedule 13G filing by Aberdeen Group plc and abrdn Inc. |
Keywords
Quoin Pharmaceuticals, Aberdeen Group, abrdn Inc., Schedule 13G, Beneficial Ownership, American Depositary Shares, ADS, Institutional Investor, SEC Filing, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.